What you want to know:

– BrightInsight, Inc., a supplier of regulated digital healthcare options, introduced an expanded multi-year partnership with Sanofi, a world biopharmaceutical firm. This expanded partnership builds on a profitable collaboration that started in 2022 when Sanofi chosen the BrightInsight Platform to speed up the event of a SaMD for one in every of its specialty healthcare medicines.

– The purpose of the collaboration is to speed up Sanofi's drug improvement timeline and enhance affected person outcomes by modern digital healthcare options.

Accelerated time-to-market for brand new therapies

Sanofi needs to chop its drug improvement timeline in half, and this collaboration with BrightInsight will play a key function in attaining that purpose. By leveraging BrightInsight's platform and expertise, Sanofi can streamline the event and implementation of digital healthcare options that assist medical trials, improve affected person engagement and enhance remedy adherence.

Enhancing the affected person expertise with “MyWay”

Below the expanded partnership, Sanofi will leverage BrightInsight's “MyWay” cellular utility, a Software program as a Medical Machine (SaMD) answer designed to empower sufferers to handle their well being situations. MyWay affords a number of essential options:

• Signs observe: This permits sufferers to observe their signs, resembling flare-ups or illness development.
• Treatment administration: Helps sufferers handle their medicines, together with injection monitoring and adherence.
• Monetary monitoring: Permits sufferers to trace medical prices in choose international locations.
• Communication care workforce: Allows direct communication with healthcare suppliers.
• Seamless consumer expertise: Supplies an easy-to-use and intuitive platform for managing well being.

“Sanofi is acknowledged globally for the transformational therapies they develop and their influence on sufferers' lives, and BrightInsight is honored to function one in every of their digital companions to create worth for these therapies,” stated Kal Patel, MD, CEO and co-founder, HelderInzicht. “The robustness of our BrightInsight Platform and Illness Administration Answer permits Sanofi to shortly launch and scale companion apps throughout manufacturers and markets, configuring every answer globally in a speedy, patient-centric and compliant method for particular illness populations and market necessities .”